Thermo Fisher Scientific Inc. (TMO) Holdings Lifted by Chesley Taft & Associates LLC

Share on StockTwits

Chesley Taft & Associates LLC grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 55,736 shares of the medical research company’s stock after buying an additional 305 shares during the quarter. Chesley Taft & Associates LLC’s holdings in Thermo Fisher Scientific were worth $13,604,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. FNY Investment Advisers LLC purchased a new stake in shares of Thermo Fisher Scientific in the second quarter worth approximately $103,000. Horrell Capital Management Inc. purchased a new stake in shares of Thermo Fisher Scientific in the second quarter worth approximately $104,000. Edge Wealth Management LLC lifted its position in shares of Thermo Fisher Scientific by 8,077.8% in the second quarter. Edge Wealth Management LLC now owns 736 shares of the medical research company’s stock worth $152,000 after purchasing an additional 727 shares in the last quarter. Atlantic Trust LLC purchased a new stake in shares of Thermo Fisher Scientific in the second quarter worth approximately $154,000. Finally, Summit Financial Group Inc. purchased a new stake in shares of Thermo Fisher Scientific in the third quarter worth approximately $201,000. Institutional investors own 85.96% of the company’s stock.

In other news, CEO Marc N. Casper sold 50,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, August 6th. The shares were sold at an average price of $233.95, for a total value of $11,697,500.00. Following the transaction, the chief executive officer now owns 320,122 shares of the company’s stock, valued at $74,892,541.90. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 125,520 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $247.50, for a total transaction of $31,066,200.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 196,070 shares of company stock worth $47,569,729. Insiders own 0.49% of the company’s stock.

TMO has been the subject of a number of research analyst reports. Goldman Sachs Group lowered shares of Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a research report on Monday, September 17th. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $261.00 price target for the company in a research report on Monday, August 6th. Barclays increased their price target on shares of Thermo Fisher Scientific from $250.00 to $275.00 and gave the stock an “overweight” rating in a research report on Monday, September 24th. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $300.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 26th. Finally, Morgan Stanley increased their price target on shares of Thermo Fisher Scientific from $233.00 to $242.00 and gave the stock an “overweight” rating in a research report on Thursday, July 26th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Thermo Fisher Scientific currently has a consensus rating of “Buy” and a consensus price target of $259.91.

Shares of TMO opened at $231.41 on Friday. The company has a market cap of $98.31 billion, a P/E ratio of 24.38, a price-to-earnings-growth ratio of 1.78 and a beta of 1.12. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.11 and a current ratio of 1.58. Thermo Fisher Scientific Inc. has a twelve month low of $181.51 and a twelve month high of $249.95.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 25th. The medical research company reported $2.75 earnings per share for the quarter, beating the consensus estimate of $2.63 by $0.12. The firm had revenue of $6.08 billion for the quarter, compared to analyst estimates of $5.90 billion. Thermo Fisher Scientific had a net margin of 10.36% and a return on equity of 16.28%. The company’s revenue for the quarter was up 21.8% on a year-over-year basis. During the same quarter last year, the firm earned $2.30 earnings per share. Analysts predict that Thermo Fisher Scientific Inc. will post 10.98 earnings per share for the current year.

Thermo Fisher Scientific declared that its board has approved a share buyback plan on Friday, September 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to reacquire up to 2.1% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Article: Why is insider trading harmful?

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply